A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults
Latest Information Update: 08 Jan 2024
At a glance
- Drugs Ganulameran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors BioNTech
- 22 Mar 2022 Status changed from active, no longer recruiting to completed.
- 21 Apr 2021 Planned number of patients changed from 144 to 96.
- 25 Feb 2021 Status changed from recruiting to active, no longer recruiting.